Fasudil and ozagrel in combination show neuroprotective effects on cerebral infarction after murine middle cerebral artery occlusion

Journal of Pharmacology and Experimental Therapeutics

Volumn 338, Issue 1, 2011, Pages 337-344

  Koumura, Akihiro ^a,b   Hamanaka, Junya ^a   Kawasaki, Koh ^c   Tsuruma, Kazuhiro ^a   Shimazawa, Masamitsu ^a   Hozumi, Isao ^b   Inuzuka, Takashi ^b   Hara, Hideaki ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^b GIFU UNIVERSITY   (Japan)

^c ASAHI KASEI PHARMA CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; FASUDIL; N(G) NITROARGININE METHYL ESTER; OZAGREL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD FLOW; BRAIN INFARCTION; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG POTENTIATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MONOTHERAPY; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; CELLS, CULTURED; CEREBRAL INFARCTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; METHACRYLATES; MICE; NEUROPROTECTIVE AGENTS; RANDOM ALLOCATION;

EID: 79959510315     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.177675     Document Type: Article

References (29)

1. Aiken JW (1984) Prostaglandins. J Cardiovasc Pharmacol 6:S413-S420.
2. Amano M, Fukata Y, and Kaibuchi K (2000) Regulation and functions of Rho-associated kinase. Exp Cell Res 261:44-51.
3. ++ influx in human platelets. Thromb Haemost 59:86-92.
4. Feske SK, Sorond FA, Henderson GV, Seto M, Hitomi A, Kawasaki K, Sasaki Y, Asano T, and Liao JK (2009) Increased leukocyte ROCK activity in patients after acute ischemic stroke. Brain Res 1257:89-93.
5. Gryglewski RJ (2008) Prostacyclin among prostanoids. Pharmacol Rep 60:3-11.
6. Hara H, Huang PL, Panahian N, Fishman MC, and Moskowitz MA (1996) Reduced brain edema and infarction volume in mice lacking the neuronal isoform of nitric oxide synthase after transient MCA occlusion. J Cereb Blood Flow Metab 16:605-611. (Pubitemid 26227069)
7. Ichikawa K, Tazawa S, Hamano S, Kojima M, and Hiraku S (1999) Effect of ozagrel on locomotor and motor coordination after transient cerebral ischemia in experimental animal models. Pharmacology 59:257-265. (Pubitemid 29473851)
8. Kataoka C, Egashira K, Inoue S, Takemoto M, Ni W, Koyanagi M, Kitamoto S, Usui M, Kaibuchi K, Shimokawa H, et al. (2002) Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by longterm blockade of nitric oxide synthesis in rats. Hypertension 39:245-250. (Pubitemid 34165223)
9. Komatsu H, Takehana Y, Hamano S, Ujiie A, and Hiraku S (1986) Beneficial effect of OKY-046, a selective thromboxane A2 synthetase inhibitor, on experimental cerebral vasospasm. Jpn J Pharmacol 41:381-391. (Pubitemid 16065347)
10. Masumoto A, Hirooka Y, Shimokawa H, Hironaga K, Setoguchi S, and Takeshita A (2001) Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension 38:1307-1310. (Pubitemid 34033407)
11. Masumoto A, Mohri M, Shimokawa H, Urakami L, Usui M, and Takeshita A (2002) Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 105:1545-1547. (Pubitemid 34297629)
12. Ming XF, Viswambharan H, Barandier C, Ruffieux J, Kaibuchi K, Rusconi S, and Yang Z (2002) Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol 22:8467-8477. (Pubitemid 35397163)
13. Miyata K, Shimokawa H, Kandabashi T, Higo T, Morishige K, Eto Y, Egashira K, Kaibuchi K, and Takeshita A (2000) Rho-kinase is involved in macrophage-mediated formation of coronary vascular lesions in pigs in vivo. Arterioscler Thromb Vasc Biol 20:2351-2358.
14. Oishi M, Mochizuki Y, Hara M, Yoshihashi H, and Takasu T (1996) Effects of sodium ozagrel on hemostatic markers and cerebral blood flow in lacunar infarction. Clin Neuropharmacol 19:526-531. (Pubitemid 26391358)
15. Osuka K, Watanabe Y, Usuda N, Nakazawa A, Tokuda M, and Yoshida J (2004) Modification of endothelial NO synthase through protein phosphorylation after forebrain cerebral ischemia/reperfusion. Stroke 35:2582-2586. (Pubitemid 39458421)
16. Pickard J, Tamura A, Stewart M, McGeorge A, and Fitch W (1980) Prostacyclin, indomethacin and the cerebral circulation. Brain Res 197:425-431. (Pubitemid 10040303)
17. Riento K and Ridley AJ (2003) Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 4:446-456. (Pubitemid 36648590)
18. Rikitake Y, Kim HH, Huang Z, Seto M, Yano K, Asano T, Moskowitz MA, and Liao JK (2005) Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 36:2251-2257. (Pubitemid 41429255)
19. Sato M, Tani E, Fujikawa H, and Kaibuchi K (2000) Involvement of Rho-kinase-mediated phosphorylation of myosin light chain in enhancement of cerebral vasospasm. Circ Res 87:195-200. (Pubitemid 30626426)
20. Sayama CM, Liu JK, and Couldwell WT (2006) Update on endovascular therapies for cerebral vasospasm induced by aneurysmal subarachnoid hemorrhage. Neurosurg Focus 21:E12.
21. Shibuya M, Hirai S, Seto M, Satoh S, Ohtomo E, and Fasudil Ischemic Stroke Study Group (2005) Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. J Neurol Sci 238:31-39.
22. Shimokawa H (2002) Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J Cardiovasc Pharmacol 39:319-327.
23. Shin HK, Salomone S, Potts EM, Lee SW, Millican E, Noma K, Huang PL, Boas DA, Liao JK, Moskowitz MA, et al. (2007) Rho-kinase inhibition acutely augments blood flow in focal cerebral ischemia via endothelial mechanisms. J Cereb Blood Flow Metab 27:998-1009. (Pubitemid 46659030)
24. Suzuki Y, Shibuya M, Satoh S, Sugiyama H, Seto M, and Takakura K (2008) Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with subarachnoid hemorrhage: sub-analysis of the post-marketing surveillance study. Neurol Med Chir (Tokyo) 48:241-247; discussion 247-248.
25. Terashita Z, Imura Y, Kawamura M, Kato K, and Nishikawa K (1995) Effects of thromboxane A2 synthase inhibitors (CV-4151 and ozagrel), aspirin, and ticlopidine on the thrombosis caused by endothelial cell injury. Thromb Res 77:411-421.
26. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, et al. (2007) Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 369:275-282. (Pubitemid 46138121)
27. Xavier FE, Blanco-Rivero J, Sastre E, Badimón L, and Balfagón G (2010) Simultaneous inhibition of TXA(2) and PGI(2) synthesis increases NO release in mesenteric resistance arteries from cirrhotic rats. Clin Sci (Lond) 119:283-292.
28. Yamashita K, Kotani Y, Nakajima Y, Shimazawa M, Yoshimura S, Nakashima S, Iwama T, and Hara H (2007) Fasudil, a Rho kinase (ROCK) inhibitor, protects against ischemic neuronal damage in vitro and in vivo by acting directly on neurons. Brain Res 1154:215-224. (Pubitemid 46856349)
29. Yano K, Kawasaki K, Hattori T, Tawara S, Toshima Y, Ikegaki I, Sasaki Y, Satoh S, Asano T, and Seto M (2008) Demonstration of elevation and localization of Rho-kinase activity in the brain of a rat model of cerebral infarction. Eur J Pharmacol 594:77-83.